A- A A+

Mal/adaptations: A qualitative evidence synthesis of opioid agonist therapy during major disruptions. 

Salamanca-Buentello F, Cheng DK, Sabioni P, Majid U, Upshur R, Sud A. 

Int J Drug Policy. 2021 Dec 10;101:103556. doi: 10.1016/j.drugpo.2021.103556. Epub ahead of print. PMID: 34902805.


The impact of COVID-19 on addiction treatment in New Zealand. 

Rodda SN, Park JJ, Wilkinson-Meyers L, King DL.

Addict Behav. 2021 Dec 27;127:107230. doi: 10.1016/j.addbeh.2021.107230. Epub ahead of print. PMID: 34996006; PMCID: PMC8711171.


Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. 

Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. 

Int J Drug Policy. 2021 Dec 20;101:103570. doi: 10.1016/j.drugpo.2021.103570. Epub ahead of print. PMID: 34954493; PMCID: PMC8685180.


The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months. 

Bennett AS, Townsend T, Elliott L. 

Int J Drug Policy. 2021 Dec 1;101:103554. doi: 10.1016/j.drugpo.2021.103554. Epub ahead of print. PMID: 34911010; PMCID: PMC8632599.


Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic-Is an update of legal restrictions warranted? 

Meyer M, Strasser J, Köck P, Walter M, Vogel M, Dürsteler KM. 

Int J Drug Policy. 2021 Nov 26;101:103548. doi: 10.1016/j.drugpo.2021.103548. Epub ahead of print. PMID: 34920218; PMCID: PMC8616744.


Implementing a Methadone Delivery System in New York City in Response to COVID-19. 

Harocopos A, Nolan ML, Goldstein GP, Mantha S, O'Neill M, Paone D. 

Am J Public Health. 2021 Dec;111(12):2115-2117. doi: 10.2105/AJPH.2021.306523. PMID: 34878865; PMCID: PMC8667852.


A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. 

Cunningham CO, Khalid L, Deng Y, Torres-Lockhart K, Masyukova M, Thomas S, Zhang C, Lu T. 

J Subst Abuse Treat. 2021 Oct 27:108641. doi: 10.1016/j.jsat.2021.108641. Epub ahead of print. PMID: 34863608; PMCID: PMC8550890.


Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey. 

Saloner B, Krawczyk N, Solomon K, Allen ST, Morris M, Haney K, Sherman SG. 

Int J Drug Policy. 2021 Nov 19;101:103537. doi: 10.1016/j.drugpo.2021.103537. Epub ahead of print. PMID: 34871945; PMCID: PMC8602971.


The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic. 

Nesoff ED, Marziali ME, Martins SS. 

Addiction. 2021 Dec 7. doi: 10.1111/add.15778. Epub ahead of print. PMID: 34873783.


Irland. Large numbers of people with drug addictions were 'left to kill themselves slowly' during lockdowns

Substance abuse support groups were closed for five months in 2020 – with catastrophic impacts for the people who attend them. (The Journal, Irland, 05.01.2022)


Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program. 

Harris R, Rosecrans A, Zoltick M, Willman C, Saxton R, Cotterell M, Bell J, Blackwell I, Page KR. 

Drug Alcohol Depend. 2022 Jan 1;230:109187. doi: 10.1016/j.drugalcdep.2021.109187. Epub 2021 Nov 26. PMID: 34890927; PMCID: PMC8619879.


COVID-19-related adaptations to the implementation and evaluation of a clinic-based intervention designed to improve opioid safety. 

Morgan AR, Hendricks MA, El Ibrahimi S, Hallvik SE, Hatch B, Dickinson C, Wright D, Fischer MA. 

Drugs Context. 2021 Dec 15;10:2021-7-5. doi: 10.7573/dic.2021-7-5. PMID: 34970321; PMCID: PMC8687093.


Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19. 

Samuels EA, Khatri UG, Snyder H, Wightman RS, Tofighi B, Krawczyk N. 

J Gen Intern Med. 2022 Jan 3:1–3. doi: 10.1007/s11606-021-07249-8. Epub ahead of print. PMID: 34981357; PMCID: PMC8722662.


Response of tertiary addictions services to opioid dependence during the COVID-19 pandemic. 

Hennigan K, Corrigan N, Killeen N, Scully M, Keenan E. 

Ir J Psychol Med. 2021 Dec;38(4):301-306. doi: 10.1017/ipm.2021.8. Epub 2021 Feb 4. PMID: 33536093; PMCID: PMC8503071.


Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms. 

Treitler PC, Bowden CF, Lloyd J, Enich M, Nyaku AN, Crystal S. 

J Subst Abuse Treat. 2022 Jan;132:108514. doi: 10.1016/j.jsat.2021.108514. Epub 2021 May 31. PMID: 34098210; PMCID: PMC8630075.


Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020. 

Chalasani R, Shinabery JM, Goetz CT, Chang CH, Yang Q, Suda KJ, Gellad WF. 

J Gen Intern Med. 2021 Dec;36(12):3915-3917. doi: 10.1007/s11606-021-07083-y. Epub 2021 Aug 10. PMID: 34378112; PMCID: PMC8354093.


Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.. 

Yeo, E.J., Kralles, H., Sternberg, D. et al.

Harm Reduct J 18, 127 (2021). doi.org/10.1186/s12954-021-00578-1


Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. 

Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT. 

Addict Sci Clin Pract. 2021 Dec 11;16(1):72. doi: 10.1186/s13722-021-00281-3. PMID: 34895346; PMCID: PMC8665717.


Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia. 

Haggerty T, Khodaverdi M, Dekeseredy P, Wood N, Hendricks B, Peklinsky J, Sedney CL. 

J Subst Abuse Treat. 2021 Dec 8:108687. doi: 10.1016/j.jsat.2021.108687. Epub ahead of print. PMID: 34903397; PMCID: PMC8651495.


Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia. 

Lintzeris, N., Deacon, R.M., Hayes, V., Cowan, T., Mills, L., Parvaresh, L., Harvey Dodds, L., Jansen, L., Dojcinovic, R., Leung, M.C., Demirkol, A., Finch, T. and Mammen, K. (2021), 

Drug Alcohol Rev.. doi.org/10.1111/dar.13382


USA. How COVID pandemic changed methadone treatment for addiction

Here’s one more lesson from the COVID-19 pandemic: It appears safe to relax restrictions on methadone, the oldest and most stigmatized treatment drug for opioid addiction. (ABC-News, USA, 12.08.2021)


"No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. 

Harris MTH, Lambert AM, Maschke AD, Bagley SM, Walley AY, Gunn CM. 

J Subst Abuse Treat. 2021 Nov 4:108655. doi: 10.1016/j.jsat.2021.108655. Epub ahead of print. PMID: 34772604; PMCID: PMC8576611.


Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19. 

Rosales R, Janssen T, Yermash J, Yap KR, Ball EL, Hartzler B, Garner BR, Becker SJ. 

J Subst Abuse Treat. 2021 Oct 30;132:108648. doi: 10.1016/j.jsat.2021.108648. Epub ahead of print. PMID: 34742607; PMCID: PMC8566093.


Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. 

Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. 

J Addict Med. 2021 Nov-Dec 01;15(6):448-451. doi: 10.1097/ADM.0000000000000791. PMID: 33298750; PMCID: PMC8562917.


Strategies Adopted by Addiction Facilities during the Coronavirus Pandemic to Support Treatment for Individuals in Recovery or Struggling with a Substance Use Disorder: A Scoping Review. 

de Vargas D, Pereira CF, Volpato RJ, Lima AVC, da Silva Ferreira R, de Oliveira SR, Aguilar TF. 

Int J Environ Res Public Health. 2021 Nov 18;18(22):12094. doi: 10.3390/ijerph182212094. PMID: 34831850; PMCID: PMC8624445.


Buprenorphine Induction in a Rural Maryland Detention Center During COVID-19: Implementation and Preliminary Outcomes of a Novel Telemedicine Treatment Program for Incarcerated Individuals With Opioid Use Disorder. 

Belcher AM, Coble K, Cole TO, Welsh CJ, Whitney A, Weintraub E. 

Front Psychiatry. 2021 Oct 28;12:703685. doi: 10.3389/fpsyt.2021.703685. PMID: 34777036; PMCID: PMC8585441.


Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care. 

Lister JJ, Lister HH. 

Rural Remote Health. 2021 Nov;21(4):6770. doi: 10.22605/RRH6770. Epub 2021 Nov 10. PMID: 34757760.


The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. 

Aponte-Melendez, Y., Mateu-Gelabert, P., Fong, C. et al.

Harm Reduct J 18, 118 (2021). doi.org/10.1186/s12954-021-00568-3


Increased illicit substance abuse among Zimbabwean adolescents and youths during the COVID-19 era: an impending public health disaster. 

Mukwenha S, Murewanhema G, Madziva R, Dzinamarira T, Herrera H, Musuka G. 

Addiction. 2021 Nov 2. doi: 10.1111/add.15729. Epub ahead of print. PMID: 34729833.


Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. 

Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I, Chaillon A, Ignacio C, Calderon A, Martin NK, Patterson TL. 

PLoS One. 2021 Nov 22;16(11):e0260286. doi: 10.1371/journal.pone.0260286. PMID: 34807963; PMCID: PMC8608290.